Logo image of CBIO

CRESCENT BIOPHARMA INC (CBIO) Stock Earnings Estimates

USA - Nasdaq - NASDAQ:CBIO - KYG2545C1042 - Common Stock

11.75 USD
-1.05 (-8.2%)
Last: 1/26/2026, 4:30:01 PM
11.75 USD
0 (0%)
After Hours: 1/26/2026, 4:30:01 PM

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
CBIO revenue by date.CBIO revenue by date.
1.16M
-88.58%
80K
-93.10%
10K
-87.50%

-100.00%
4.59M6.12M
33.33%
39.454M
544.67%
114.49M
190.19%
318.55M
178.23%
645.88M
102.76%
1.075B
66.44%
EBITDA
YoY % growth
CBIO ebitda by date.CBIO ebitda by date.
-63.19M
-23.32%
-47.19M
25.32%
-39.122M
17.10%
N/A
16.99%
N/AN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
CBIO ebit by date.CBIO ebit by date.
-63.45M
-23.18%
-47.4M
25.30%
-39.275M
17.14%
-33.887M
17.23%
-102.035M
-213.86%
-116.709M
-14.38%
-145.661M
-24.81%
-177.287M
-21.71%
-203.038M
-14.52%
-187.942M
7.43%
-152.063M
19.09%
76.023M
149.99%
466.18M
513.21%
Operating Margin
CBIO operating margin by date.CBIO operating margin by date.
-5,469.83%-59,250.00%-392,753.00%N/AN/AN/A-3,173.43%-2,896.85%-514.62%-164.16%-47.74%11.77%43.37%
EPS
YoY % growth
CBIO eps by date.CBIO eps by date.
-123.00
-10.81%
-88.00
28.46%
-58.00
34.09%
-0.62
98.93%
-7.80
-1,159.26%
-5.51
29.33%
-3.84
30.36%
-4.11
-7.13%
-5.26
-27.81%
-4.02
23.57%
-3.43
14.72%
4.40
228.27%
16.51
275.64%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 25 Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth
-2.32
-1,324.11%
-2.76
30.94%
-2.86
42.07%
-1.50
-17.80%
-1.50
35.60%
Revenue
Q2Q % growth
4.08M
-100.00%
EBITDA
Q2Q % growth
N/AN/AN/AN/AN/A
EBIT
Q2Q % growth
-35.766M
-572.89%
-22.466M
-529.29%
-22.925M
-99.09%
-23.486M
5.61%
-23.996M
32.91%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2025
Q2Q % growth
-1.27
-1,031.91%
-2.020.7537.18%
Q2 2025
Q2Q % growth
-4.93
69.19%
-1.80-3.13-174.23%
Q1 2025
Q2Q % growth
-4.00
76.47%
-5.101.1021.57%
Q4 2024
Q2Q % growth

98.83%
-0.16%
Q3 2024
Q2Q % growth

99.20%
-0.11%
Q2 2024
Q2Q % growth
-16.00
-23.08%
-17.091.096.35%
Q1 2024
Q2Q % growth
-17.00 -16.83-0.17-1.01%
Q4 2023
Q2Q % growth
-14.00
26.32%
-15.561.5510.00%
Q3 2023
Q2Q % growth
-14.00
12.50%
-14.620.624.24%
Q2 2023
Q2Q % growth
-13.00
48.00%
-18.705.7030.48%
Q1 2023
Q2Q % growth
-17.00
39.29%
-17.000.000.00%
Q4 2022
Q2Q % growth
-19.00
42.42%
-17.00-2.00-11.76%
Q3 2022
Q2Q % growth
-16.00
52.94%
-26.8610.8640.43%
Q2 2022
Q2Q % growth
-25.00
10.71%
-29.074.0714.00%
Q1 2022
Q2Q % growth
-28.00 -31.283.2810.49%
Q4 2021
Q2Q % growth
-33.00
-3.13%
-34.431.424.14%
Q3 2021
Q2Q % growth
-34.00
-17.24%
-32.39-1.62-4.99%
Q2 2021
Q2Q % growth
-28.00
12.50%
-31.373.3710.73%
Q1 2021
Q2Q % growth
-28.00
-55.56%
-32.444.4413.68%
Q4 2020
Q2Q % growth
-32.00 -32.840.842.57%
Q3 2020
Q2Q % growth
-29.00 -33.464.4613.32%
Q2 2020
Q2Q % growth
-32.00 -38.766.7617.44%
Q1 2020
Q2Q % growth
-18.00 -31.0113.0141.95%
CBIO Yearly EPS VS EstimatesCBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -50 -100 -150
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2024
Q2Q % growth

-100.00%
%
Q2 2023
Q2Q % growth

-100.00%
%
Q4 2022
Q2Q % growth

-100.00%
%
Q3 2022
Q2Q % growth

-100.00%
%
Q1 2022
Q2Q % growth

-100.00%
%
Q4 2021
Q2Q % growth
20K
-87.50%
20K%
Q3 2021
Q2Q % growth
90K
-91.00%
90K%
Q1 2021
Q2Q % growth
1.06M
-88.22%
1.06M%
Q4 2020
Q2Q % growth
160K 204K-44K-21.57%
CBIO Yearly Revenue VS EstimatesCBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2020 2021 2022 2023 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 0% 0% -6.03%
RevenueN/A N/A -100% N/A